Alla Yu. Savchenko

Alla Yu. Savchenko

Auto-generated profile, based on publicly available information

Alla Yu. Savchenko

National Research Nuclear University MEPhI

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
VSV.P. Skulachev
V.P. Skulachev
YAY. N. Antonenko
Y. N. Antonenko
VAV. N. Anisimov
V. N. Anisimov
Boris V. ChernyakBoris V. Chernyak
Boris V. Chernyak
NDNikolay Denisov
Nikolay Denisov
VSV. P. Skulachev
V. P. Skulachev
Plastoquinone, a very effective electron carrier and antioxidant of chloroplasts, was conjugated with decyltriphenylphosphonium to obtain a cation easily penetrating through membranes. This cation, called SkQ1, is specifically targeted to mitochondria by electrophoresis in the electric field formed by the mitochondrial respiratory chain. The respiratory chain also regenerates reduced SkQ1H2 from its oxidized form that appears as a result of the antioxidant activity of SkQ1H2. SkQ1H2 prevents oxidation of cardiolipin, a mitochondrial phospholipid that is especially sensitive to attack by reactive oxygen species (ROS). In cell cultures, SkQ1 and its analog plastoquinonyl decylrhodamine 19 (SkQR1) arrest H2O2-induced apoptosis. When tested in vivo, SkQs (i) prolong the lifespan of fungi, crustaceans, insects, fish, and mice, (ii) suppress appearance of a large number of traits typical for age-related senescence (cataract, retinopathies, achromotrichia, osteoporosis, lordokyphosis, decline of the immune system, myeloid shift of blood cells, activation of apoptosis, induction of β-galactosidase, phosphorylation of H2AX histones, etc.) and (iii) lower tissue damage and save the lives of young animals after treatments resulting in kidney ischemia, rhabdomyolysis, heart attack, arrhythmia, and stroke. We suggest that the SkQs reduce mitochondrial ROS and, as a consequence, inhibit mitochondriamediated apoptosis, an obligatory step of execution of programs responsible for both senescence and fast “biochemical suicide” of an organism after a severe metabolic crisis.

11 December 2015 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
VBVladimir V. Brzheskiy
Vladimir V. Brzheskiy
EEElena L. Efimova
Elena L. Efimova
TVTatiana N. Vorontsova
Tatiana N. Vorontsova
VAVladimir N. Alekseev
Vladimir N. Alekseev
OGOlga G. Gusarevich
Olga G. Gusarevich
MSMaxim V. Skulachev
Maxim V. Skulachev
Introduction This article presents the results of an international, multicenter, randomized, double-masked, placebo-controlled clinical study of Visomitin (Mitotech LLC, Moscow, Russian Federation) eye drops in patients with dry eye syndrome (DES). Visomitin is the first registered (in Russia) drug with a mitochondria-targeted antioxidant (SkQ1) as the active ingredient. Methods In this multicenter (10 sites) study of 240 subjects with DES, study drug (Visomitin or placebo) was self-administered three times daily (TID) for 6 weeks, followed by a 6-week follow-up period. Seven in-office study visits occurred every 2 weeks during both the treatment and follow-up periods. Efficacy measures included Schirmer’s test, tear break-up time, fluorescein staining, meniscus height, and visual acuity. Safety measures included adverse events, slit lamp biomicroscopy, tonometry, blood pressure, and heart rate. Tolerability was also evaluated. Results This clinical study showed the effectiveness of Visomitin eye drops in the treatment of signs and symptoms of DES compared with placebo. The study showed that a 6-week course of TID topical instillation of Visomitin significantly improved the functional state of the cornea; Visomitin increased tear film stability and reduced corneal damage. Significant reduction of dry eye symptoms (such as dryness, burning, grittiness, and blurred vision) was also observed. Conclusion Based on the results of this study, Visomitin is effective and safe for use in eye patients with DES for protection from corneal damage. Funding Mitotech LLC.

1 October 2012 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
ISIgor Shohin
Igor Shohin
JKJulia I. Kulinich
Julia I. Kulinich
GRGalina Ramenskaya
Galina Ramenskaya
BABertil Abrahamsson
Bertil Abrahamsson
SKSabine Kopp
Sabine Kopp
JDJennifer B. Dressman
Jennifer B. Dressman

1 November 2013 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
VKVladimir Kokorekin
Vladimir Kokorekin
Alexander Terent'evAlexander Terent'ev
Alexander Terent'ev
GRGalina Ramenskaya
Galina Ramenskaya
GNGrammatikova Natalia
Grammatikova Natalia
GRG. M. Rodionova
G. M. Rodionova
AIA. I. Ilovaiskii
A. I. Ilovaiskii

1 July 2018 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
DSDmitry Sychev
Dmitry Sychev
ALAlexander Nikolaevich Levanov
Alexander Nikolaevich Levanov
TSTatiana Vladimirovna Shelekhova
Tatiana Vladimirovna Shelekhova
PBPavel Olegovich Bochkov
Pavel Olegovich Bochkov
NDNatalia Pavlovna Denisenko
Natalia Pavlovna Denisenko
TBTanya Bogoslovsky
Tanya Bogoslovsky
Background: Non-vitamin K oral anticoagulants (NOACs) are commonly used for prophylaxis of venous thromboembolism (VTE) in orthopedic patients. Despite known safety and high potency of NOACs, potential interactions of NOACs with genetic polymorphisms are poorly understood. Dabigatran etexilate is one of the most commonly prescribed direct thrombin inhibitors for the prevention of VTE. The objectives of this study were to assess the effect of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) polymorphisms on dabigatran pharmacokinetics in patients after total knee arthroplasty. Patients and methods: A total of 60 patients, aged 37–81 years, who underwent surgery for knee replacement have been included in the study. VTE prophylaxis was conducted via administration of dabigatran etexilate 220 mg once daily. Genotyping for carrier state of polymorphic variants such as rs1045642 and rs4148738 of the ABCB1 gene and rs2244613 of the CES1 gene was carried out using real-time polymerase chain reaction (PCR). We also measured the peak and trough concentrations of plasma dabigatran by using high-performance liquid chromatography (HPLC). Results: Our study revealed that TT genotype of rs1045642 polymorphism of the ABCB1 gene was associated with higher dabigatran equilibrium peak concentrations and the higher risk of bleeding than the presence of CC genotype (p<0.008). There was no statistically significant genotype-dependent difference in the trough concentrations between rs1045642 and rs4148738 of the ABCB1 gene and rs2244613 of the CES1 gene. Conclusion: Our findings indicate that the polymorphisms of ABCB1 rs1045642 may have a prominent contribution to the safety of dabigatran in patients after knee surgery. Moreover, TT genotype may be associated with the higher risk of hemorrhagic complications in this population. There were no influence of polymorphism of ABCB1 rs4148738 and CES1 rs2244613 on dabigatran peak and through concentrations. Larger studies are needed to confirm our observations.

1 August 2014 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
IPI. B. Perova
I. B. Perova
AZA. A. Zhogova
A. A. Zhogova
ACA. V. Cherkashin
A. V. Cherkashin
KÉK. I. Éller
K. I. Éller
GRGalina Ramenskaya
Galina Ramenskaya
ISI. A. Samylina
I. A. Samylina